Related Experiment Video
Updated: May 16, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Prognostic factors in surgically managed gastrointestinal stromal tumours
1Department of Colorectal Surgery, Cancer Centre, Sun Yat-sen University/State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.
Objective:
To determine prognostic factors associated with survival in patients with surgically managed gastrointestinal stromal tumours (GISTs).
Methods:
This retrospective study included 374 patients with pathologically confirmed GISTs. Medical records were reviewed and prognostic factors associated with adverse outcomes were determined.
Results:
A total of 337 patients underwent complete resection with curative intent; 37 underwent incomplete resection. Overall mean survival time was 127.3 months; 5-year survival rate was 70.4%. Multivariate analyses determined that tumour size, risk status (of recurrence or metastasis) and surgical procedure were significant predictive factors for survival. There was a significant difference in the 5-year survival rate between patients who received adjuvant imatinib compared with those who did not (75.1% versus 13.8%).
Conclusions:
Patients with GISTs managed by surgical resection combined with targeted chemotherapy had a good prognosis. Clinical factors predictive of survival included tumour size, risk status and surgical procedure.